Subscribe to daily environment news





 

Click for news Click for pictures
National Tree Day

Planet Ark Home


Pfizer to Pay US$975,000 for Clean Air Violations
Mail this story to a friend | Printer friendly version

US: June 25, 2008


NEW YORK - Pfizer Inc has agreed to pay $975,000 to resolve alleged violations of the Clean Air Act at a former manufacturing plant in Groton, Connecticut, the Justice Department and Environmental Protection Agency (EPA) announced Monday.


The agencies said the settlement was the first of its kind in federal court under regulations designed to control emissions of hazardous air pollutants from drug makers' manufacturing operations.

Under the consent decree filed in US District Court in Connecticut, Pfizer certifies the violations have been corrected. But the violations undermined EPA's ability to determine compliance, the agency said in a statement.

The alleged violations, which occurred between October 2002 and December 2005, resulted from a failure of Pfizer's leak detection and repair program, which presented the risk of excess emissions of hazardous air pollutants, the Justice Dept. and EPA said in a news release.

During its production of pharmaceutical-grade chemicals, Pfizer used substances such as methanol, hydrogen chloride, methylene chloride, MTBE, hexane, toluene and many others, which are classified by EPA as hazardous air pollutants.

"All facilities that produce hazardous air pollutants must carefully adhere to all provisions of EPA's Clean Air requirements to ensure that we are taking every necessary step to protect human health and our environment," Robert Varney, regional administrator of EPA's New England office, said in a statement.

Pfizer, the world's largest drug maker, said in a statement it agreed to pay the civil penalty, even though it "believes that the penalty sought by the government is not commensurate with the nature of the alleged violations."

Pfizer said it took timely steps to enhance compliance of its program and ensure the agency's concerns were addressed. In addition, the drug maker said it has no reason to believe "that the alleged deficiencies resulted in any environmental harm."

The specific violations included a failure to properly conduct pressure tests to identify leaks, repair leaks before start-up, equip open-ended lines with a cap or other seal and document leak tests to establish full compliance with requirements, the news release said.

The Groton facility that was cited ceased pharmaceutical manufacturing in January. (Reporting by Bill Berkrot; Editing by Andre Grenon)


REUTERS NEWS SERVICE

Reuters



© 2008 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content, including by framing or similar means, is expressly prohibited without the prior written consent of Reuters.
top

 
TODAY'S
ENVIRONMENT
NEWS

AUSTRALIA:
Malaria and Dengue the Sting in Climate Change

AUSTRALIA:
Torrential Rains Hit Australia State, One Dead

BELGIUM:
Global Warming Could Lead To More Arctic Energy

BELGIUM/UK:
Not Promising The Earth, Ethical Banks Win Custom

GERMANY/BELGIUM:
EU Carmaking Nations in CO2 Deal as Italy Signs Up

SINGAPORE:
Aussie Miners Turn To Solar Tower Power

SPAIN:
Greenpeace Blockades Ageing Spanish Nuclear Plant

UK:
UN Publishes Draft Proposal Ahead of Climate Meet

US:
ANALYSIS - Weak Economy Could Curb Obama Coal Cleanup Plan

US:
Volkswagen Diesel Car Wins "Green Car of the Year"

US:
Automakers Detail Electric Car Plans at LA Show

US:
Wal-Mart in Wind Energy Deal with Duke Energy

US:
Broad Schwarzenegger Emissions Pledge Caps Summit

US:
Ex-EPA Official Faults Probe of BP Pipeline Spills



previous day